Peng Xu (SPH’12)

Peng Xu, BUSPH2012, is currently an advisor/venture partner at Centennial & Huivalue Group (CHG), a China-based boutique firm that advises Biotech and Pharma companies in critical cross-border issues focusing on business development and market access. Previously, Peng held strategic and operation leadership roles in both emerging biotech (Cubist, a Boston-based biotech acquired by Merck) and established biopharma (Celgene, Gilead). He also had clinical strategy and management consulting experiences at IQVIA. Peng began his professional career as a research analyst while pursuing his master’s degree with the BU School of Public Health (SPH), where he spent two amazing years in the historic Talbot Building.

Guided by the values he learned at SPH, Peng is passionate about positively impacting people’s health, either through research or medicine. His two proud moments are that he helped Revlimid get onto China’s national formulary so that tens of thousands multiple myeloma patients can afford this medicine; and that, together with his mentors/professors at SPH, he published research investigating the quality of care among Medicare patients, at a premier journal, the Annals of Internal Medicine.